SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULE 13D-1(b), (c) AND (d)
AND AMENDMENTS THERETO FILED PURSUANT TO 13D-2(b)

                 Acasti Pharma Inc.              
(Name of Issuer)

      Common Shares      
(Title of Class of Securities)

                          00430K105                           
(CUSIP Number)

                      October 23, 2018                        
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     [   ] Rule 13d-1 (b)
     [X] Rule 13d-1 (c)
     [   ] Rule 13d-1 (d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Item 1(a).     Name of Issuer: Acasti Pharma Inc.

This Schedule 13G is being filed on behalf of Acuitas Group Holdings, LLC (“Acuitas”) and Terren S. Peizer, as joint filers (collectively, the "Reporting Persons").

The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit A, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

The principal business office of the Reporting Persons is 2120 Colorado Avenue, #230, Santa Monica, California 90404. For citizenship, see Item 4 of each cover page.

Item 2(d).          Title of Class of Securities: Common Shares

Item 2(e).          CUSIP Number: 00430K105

Item 3.              Not Applicable

Item 4.             Ownership:     

(a)     Amount Beneficially Owned: Amount beneficially owned: 8,650,000 shares which includes (i) 5,000,000 common shares held by Acuitas and (ii) 3,650,000 common shares issuable upon the exercise of currently exercisable warrants held by Acuitas.

(b)     Percent of Class: 10.58%, based on 78,132,734 common shares outstanding as of March 31, 2019

(c)     Number of shares as to which such person has:

(i)     sole power to vote or to direct the vote: 8.650,000

(ii)     shared power to vote or to direct the vote: 8,650,000

(iii)     sole power to dispose or to direct the disposition of: 8,650,000

(iv)     shared power to dispose or to direct the disposition of: 8,650,000

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated:     July 19, 2019     

EXHIBIT A

AGREEMENT REGARDING JOINT FILING

OF STATEMENT ON SCHEDULE 13D OR 13G

The undersigned agree to file jointly with the Securities and Exchange Commission (the "SEC") any and all statements on Schedule 13D or Schedule 13G (and any amendments or supplements thereto) required under section 13(d) of the Securities Exchange Act of 1934, as amended, in connection with purchases and sales by the undersigned of the securities of Acasti Pharma Inc.. until such time as the undersigned file with the SEC a statement terminating this Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G.  

Dated: July 19, 2019